Breast: OPERA-02
Trial ID
07085767
Trial Sponsor
Olema Pharmaceuticals, Inc
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant with Ribociclib Versus Letrozole with Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer